Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
152 Results for "
CYP2C9
" in MedChemExpress (MCE) Product Catalog:
Products (152)
152 Results for "CYP2C9" in MCE Product Catalog:
Cat. No.: HY-121698
CAS No.: 1373353-95-7
Target:
Research Areas:
GW694481 is an ApoA1 upregulator with IC50 values of 2.1 μM for CYP2C9 inhibition and 17.0 μM for CYP3A4 inhibition. GW694481 upregulates ApoA1 expression in human hepatic cells.GW694481 can be used for the research of atherosclerosis .
Cat. No.: HY-182602
CAS No.: 693272-98-9
Target:
Research Areas:
KOSN 1724 is an anticancer agent. KOSN 1724 disrupts tubulin activity, stabilizes microtubules, and inhibits cancer cells proliferation. KOSN 1724 inhibits cytochrome P450 3A4, CYP2C9, and CYP2C19 activity. KOSN 1724 can be used for the research of cancer .
Cat. No.: HY-100641S1
Synonyms: Hydroxytolbutamide-d9-1
Cat. No.: HY-117925
CAS No.: 1529779-90-5
Personalised postprandial-targeting is a way to modulate water-heme interactions with activity against low-spin P450 complexes. Personalised postprandial-targeting is able to maintain the axial water ligands of CYP2C9 even in the presence of inhibitors. Personalised postprandial-targeting also allows the hydrogen atoms of the axial water ligands to be observed by EPR spectroscopy, providing insights into the enzyme active site .
Cat. No.: HY-122163
CAS No.: 1149750-69-5
Research Areas:
MK-3901 is a selective P2X3 receptor antagonist with an IC50 of 24 nM. MK-3901 inhibits UGT1A1 (with an IC50 of 1 μM) and CYP2C9 (with an IC50 of 5.7 μM). MK-3901 activates PXR. MK-3901 induces hyperbilirubinemia. MK-3901 can be used for the research of inflammatory pain .
Cat. No.: HY-180227
Target:
Research Areas:
URAT1-IN-15 (Compound 9) is an orally active, selective URAT1 inhibitor with an IC50 of 69.81 nM. URAT1-IN-15 inhibits CYP2C9 (IC50 = 8.39 μM). URAT1-IN-15 shows uricosuric activity. URAT1-IN-15 can be used in the research of hyperuricemia .
Cat. No.: HY-W413619
CAS No.: 1193314-24-7
Synonyms: NITD609 enantiomer; KAE609 enantiomer
Cipargamin enantiomer (NITD609 enantiomer) is a Plasmodium falciparum inhibitor that can be characterized as a spirotetrahydro β-carboline (1S,3R stereoisomer). Cipargamin enantiomer exerts antiplasmodial activity against Plasmodium falciparum strains NF54 (IC50 of 77 nM) and K1. Cipargamin enantiomer displays low liver microsomal intrinsic clearance in mouse and human systems. Cipargamin enantiomer does not inhibit CYP2C9. Cipargamin enantiomer can be used for the research of malaria .
Cat. No.: HY-115548
CAS No.: 1443735-02-1
Target:
Research Areas:
ROMK-IN-1 is an orally active inhibitor of ROMK (Kir1.1) with an IC50 of 0.073 μM. ROMK-IN-1 exhibits no activity against Kir2.1, Kir4.1, Kir7.1, Nav1.5, Cav1.2, as well as the enzymes CYP3A4, CYP2D6, and CYP2C9. ROMK-IN-1 can be used in research related to hypertension .
Cat. No.: HY-50856BS
CAS No.: 2147706-60-1
Synonyms: CTP-543 phosphate; Ruxolitinib-d8 phosphate; INCB18424-d8 (phospha
Target:
Research Areas:
Deuruxolitinib phosphate (CTP-543 phosphate; Ruxolitinib-d8 phosphate) is a deuterated analog of Ruxolitinib (HY-50856) and an orally active, selective inhibitor of JAK1 and JAK2. Deuruxolitinib phosphate blocks Janus kinase-mediated cytokine receptor signaling and proinflammatory cytokine gene expression. Deuruxolitinib phosphate is primarily metabolized in the liver via CYP2C9. Deuruxolitinib phosphate promotes scalp hair regrowth in severe chronic alopecia areata. Deuruxolitinib phosphate is used in alopecia areata-related research .
Cat. No.: HY-166530S
Cat. No.: HY-182965
CAS No.: 2756355-59-4
Research Areas:
Glucocorticoid receptor antagonist-1 is an orally active glucocorticoid receptor (GR) antagonist with an IC50 of 27 nM and a Ki value of 32 nM, and it exhibits low agonist activity. Glucocorticoid receptor antagonist-1 shows moderate inhibitory effects on CYP2C9 and CYP2D6, and potent inhibitory effect on CYP2C8. Glucocorticoid receptor antagonist-1 prevents Olanzapine (HY-14541)-induced weight gain in female rats. Glucocorticoid receptor antagonist-1 can be used in studies related to weight gain .
Cat. No.: HY-W707554
CAS No.: 2985259-58-1
Cat. No.: HY-W739842
CAS No.: 17834-04-7
Synonyms: 8-OH Warfarin
Target:
Research Areas:
8-Hydroxywarfarin (8-OH Warfarin) is a CYP2C9 inhibitor. 8-Hydroxywarfarin inactivates the anticoagulant activity of Warfarin (HY-B0687) via 8-hydroxylation. 8-Hydroxywarfarin serves as a glucuronidation substrate for UGT1A1, UGT1A8, UGT1A9, as well as wild-type/mutant UGT1A10. This reaction enhances its polarity, solubility and excretion efficiency, and the process is independent of phenylalanine 90 of UGT1A10. 8-Hydroxywarfarin can be used in studies related to thromboembolic diseases .
Cat. No.: HY-135111S
CAS No.: 1794759-05-9
4-Desmethoxy Omeprazole-d3 is the deuterated-labeled 4-Desmethoxy Omeprazole (HY-135111). 4-Desmethoxy Omeprazole is a metabolite of Omeprazole (HY-B0113) and an impurity in its preparation process. Omeprazole is an orally active H+,K+-ATPase inhibitor and also a proton pump inhibitor. Omeprazole competitively inhibits the activity of CYP2C19, CYP3A4, and CYP2C9. Omeprazole inhibits gastric acid secretion and can be used for the treatment of acid-related gastrointestinal disorders. Omeprazole also has neuroprotective and antibacterial effects .
Cat. No.: HY-173032
Target:
Research Areas:
VU6033685 is the orally active positive allosteric modulator (PAM) for mGlu1 that positively modulates human mGlu1 and human mGlu5 with EC50 of 39 nM and 3960 nM. VU6033685 also inhibits CYP1A2, CYP2C9 and CYP2D6 with IC50 of 26, 22.3 and 23.8 μM, respectively. VU6033685 reverses amphetamine-induced rats hyperlocomotion, protects rats from MK-801 (HY-15084B)-induced cognitive impairment. VU6033685 exhibits good pharmacokinetics characteristics in rats with an oral bioavailability of 42.8% .
Cat. No.: HY-181611
CAS No.: 3068829-46-6
Research Areas:
Polθ-IN-10 is an orally active Polθ-pol inhibitor (with a human IC50 of 1.3 nM) that exhibits oral bioavailability in mice and rats. Polθ-IN-10 binds to the allosteric site of Polθ-pol, disrupts the microhomology-mediated end-joining DNA repair pathway, and inhibits CYP2C9 (IC50=1.63 μM). Polθ-IN-10 selectively inhibits the proliferation of HR-deficient cancer cells and induces apoptosis. Polθ-IN-10 is applicable to the research of HR-deficient cancers .
Cat. No.: HY-19397
CAS No.: 275375-69-4
Target:
Research Areas:
BMS-223131 (Compound 1) is a potent maxi-K potassium channel opener. BMS-223131 has a strong inhibitory effect on the CYP2C9 enzyme (IC50 = 1.7 μM) and also shows varying degrees of inhibition on other common CYP enzymes such as CYP1A2, CYP2C19, CYP2D6, and CYP3A4. BMS-223131 can enhance the outward current mediated by maxi-K, by promoting K + efflux to hyperpolarize the cell membrane and reducing Ca 2+ influx. BMS-223131 can be used for the research of neurological disease, such as stroke .
Cat. No.: HY-76520S
Synonyms: IPI 1040-13C6 ; TBC-11251-13C6
Cat. No.: HY-B0153AR
CAS No.: 53885-35-1
Research Areas:
Ticlopidine hydrochloride (Standard) is the analytical standard of Ticlopidine hydrochloride (HY-B0153A). This product is intended for research and analytical applications. Ticlopidine (PCR 5332) hydrochloride, an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine hydrochloride blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine hydrochloride is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine hydrochloride inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively .
Cat. No.: HY-10575
CAS No.: 1044586-68-6
Target:
Research Areas:
MK-5596 is an efficient, selective and orally active CB1R (IC50 = 1.0 nM, EC50 = 5.8 nM) inverse agonist. MK-5596 has weak hERG inhibitory activity. MK-5596 has strong weight loss and appetite suppression effects. MK-5596 has a certain inhibitory effect on CYP enzymes (CYP3A4: IC50 = 3.3 μM, CYP2C8: IC50 = 11 μM, CYP2C9: IC50 = 18 μM, CYP2D6: IC50 = 6 μM). MK-5596 can be used for research on conditions such as obesity .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
